Introduction: Surgical treatment is accepted as conventional treatment of patients with acute aortic syndrome associated to ischemic complications. Promising results of thoracic endovascular aortic repair (TEVAR) has expanded its indication to a variety of thoracic aorta pathologies.
Objectives: The objective of this study was to evaluate the safety and efficacy of TEVAR during the in-hospital period and at mid-term follow-up, and compare with medical and surgical treatment in patients who presented with acute aortic syndrome (AAS) type B.
Cardiac surgery is an area in which coagulation monitoring has vital applications. Cardiopulmonary bypass (CPB) procedures could not be performed without an effective method of preventing blood from clotting in the extracorporeal circuit. In the early part of the twentieth century, heparin was discovered to have anticoagulant properties; it remains the anticoagulant most commonly used during CPB.
View Article and Find Full Text PDF